Angiotech Pharmaceuticals announces the commercial launch of the Option(TM) Inferior Vena Cava Filter in the United States



    VANCOUVER, Aug. 20 /CNW/ - Angiotech Pharmaceuticals, Inc. (NASDAQ:   ANPI;
TSX: ANP), today announced the commercial launch of the Option(TM) Inferior
Vena Cava (IVC) Filter in the United States, following FDA 510(k) clearance in
June and a limited pre-launch in July. Angiotech holds exclusive worldwide
rights to market and distribute the Option IVC Filter, which it obtained in a
license agreement with privately held Rex Medical, LP (Rex Medical), as
announced in March 2008.
    "The pre-launch of the Option IVC Filter last month was overwhelmingly
successful, demonstrating its potential to be a market leading product in
pulmonary embolism prevention," said Dr. William Hunter, President and CEO of
Angiotech. "We are excited to announce that the Option IVC Filter is now
available throughout the U.S. through our dedicated Interventional Sales
team."
    The Option IVC Filter is used for the prevention of recurrent pulmonary
embolism (PE). The device is implanted, typically by Interventional
Radiologists in a minimally invasive procedure, into the body's inferior vena
cava to prevent PE. The Option IVC Filter is specifically designed for use as
both a permanent or temporary implant (in temporary, or retrievable,
indications, a physician may later perform a second surgical procedure to
remove the Option IVC Filter if necessary or where mandated clinically).

    About the Option(TM) Inferior Vena Cava Filter

    The Option IVC Filter, developed by Rex Medical, is specifically designed
to facilitate long-term retrieval post device implantation if desired or
deemed necessary by the treating physician, and can be used in the following
conditions: pulmonary thromboembolism when anticoagulant therapy is
contraindicated, failure of anticoagulant therapy in thromboembolic diseases,
emergency treatment following massive PE where anticipated benefits of
conventional therapy are reduced, and chronic recurrent PE when anticoagulant
therapy has failed or is contraindicated. The nitinol, Option(TM) IVC Filter,
with a low profile delivery system, is designed with struts which direct clot
volume into the center of the vessel for maximum dissolution and preservation
of blood flow, allowing for capture of clinically significant clot and
protection against PE. The self-centering filter facilitates optimal
positioning and stability within the inferior vena cava.

    About Pulmonary Embolism (PE)

    PE is an extremely common and highly lethal condition. PE is the sudden
blocking of an artery of the lung (pulmonary artery) by a collection of solid
material brought through the bloodstream (embolus) - usually a blood clot
(thrombus) or other foreign material. PE occurs when these clots break loose
and "embolize" to block pulmonary blood vessels in the lungs. According to
clinical research, if left untreated, PE has a mortality rate of 30%. Emboli
dislodgement can be caused by peripheral vascular disease (PVD), severe deep
vein thrombosis (DVT), trauma and, prolonged immobilization often following a
major surgical procedure.

    
    Forward Looking Statements
    --------------------------
    

    Statements contained in this press release that are not based on
historical fact, including without limitation statements containing the words
"believes," "may," "plans," "will," "estimates," "continues," "anticipates,"
"intends," "expects" and similar expressions, constitute "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995 and constitute "forward-looking information" within the meaning of
applicable Canadian securities laws. All such statements are made pursuant to
the "safe harbor" provisions of applicable securities legislation.
Forward-looking statements may involve, but are not limited to, comments with
respect to our objectives and priorities for the remainder of 2009 and beyond,
our strategies or future actions, our targets, expectations for our financial
condition and the results of, or outlook for, our operations, research and
development and product and drug development. Such forward-looking statements
involve known and unknown risks, uncertainties and other factors that may
cause the actual results, events or developments to be materially different
from any future results, events or developments expressed or implied by such
forward-looking statements. Many such known risks, uncertainties and other
factors are taken into account as part of our assumptions underlying these
forward-looking statements and include, among others, the following: general
economic and business conditions in the United States, Canada and the other
regions in which we operate; market demand; technological changes that could
impact our existing products or our ability to develop and commercialize
future products; competition; existing governmental regulations and changes
in, or the failure to comply with, governmental regulations; availability of
financial reimbursement coverage from governmental and third-party payers for
products and related treatments; adverse results or unexpected delays in
pre-clinical and clinical product development processes; adverse findings
related to the safety and/or efficacy of our products or products sold by our
partners; decisions, and the timing of decisions, made by health regulatory
agencies regarding approval of our technology and products; the requirement
for substantial funding to conduct research and development, to expand
manufacturing and commercialization activities; and any other factors that may
affect our performance. In addition, our business is subject to certain
operating risks that may cause any results expressed or implied by the
forward-looking statements in this Quarterly Report on Form 10-Q to differ
materially from our actual results. These operating risks include: our ability
to attract and retain qualified personnel; our ability to successfully
complete pre-clinical and clinical development of our products; changes in our
business strategy or development plans; our failure to obtain patent
protection for discoveries; loss of patent protection resulting from
third-party challenges to our patents; commercialization limitations imposed
by patents owned or controlled by third parties; our ability to obtain rights
to technology from licensors; liability for patent claims and other claims
asserted against us; our ability to obtain and enforce timely patent and other
intellectual property protection for our technology and products; the ability
to enter into, and to maintain, corporate alliances relating to the
development and commercialization of our technology and products; market
acceptance of our technology and products; our ability to successfully
manufacture, market and sell our products; the availability of capital to
finance our activities; our ability to restructure and to service our debt
obligations; and any other factors referenced in our other filings with the
applicable Canadian securities regulatory authorities or the Securities and
Exchange Commission ("SEC"). For a more thorough discussion of the risks
associated with our business, see the "Risk Factors" section in our annual
report for the year ended December 31, 2008 filed with the SEC on Form 10-K,
and our quarterly report for the three months ended June 30, 2009 filed with
the SEC on Form 10-Q.
    Given these uncertainties, assumptions and risk factors, investors are
cautioned not to place undue reliance on such forward-looking statements.
Except as required by law, we disclaim any obligation to update any such
factors or to publicly announce the result of any revisions to any of the
forward-looking statements contained in this press release to reflect future
results, events or developments.

    
    (C)2009 Angiotech Pharmaceuticals, Inc. All Rights Reserved.

    About Angiotech Pharmaceuticals
    

    Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and
medical device company with over 1,500 dedicated employees. Angiotech
discovers, develops and markets innovative treatment solutions for diseases or
complications associated with medical device implants, surgical interventions
and acute injury. To find out more about Angiotech (NASDAQ:   ANPI, TSX: ANP),
please visit our website at www.angiotech.com.

    About Rex Medical, LP

    Rex Medical, LP, based in Conshohocken, PA, is a privately held medical
device company specializing in the development, manufacturing and marketing of
minimally invasive medical devices targeted towards the cardiovascular, venous
access, endosurgery and oncology markets.
    Option(TM) is a trademark of Rex Medical, LP, used under license by
Angiotech.





For further information:

For further information: DeDe Sheel, Investor Relations and Corporate
Communications, Angiotech Pharmaceuticals, Inc., (415) 293-4412,
dede.sheel@fd.com

Organization Profile

Angiotech Pharmaceuticals, Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890